Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below
The STEP pooled analysis showed weight loss was roughly the same whether patients had GI symptoms or not
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
The next two to three years will bring significant developments in Retatrutide availability
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
This GLP-1 receptor agonist has shown effectiveness in achieving substantial weight loss by boosting feelings of fullness and decreasing hunger
